Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy

doi:10.3760/cma.j.cn371439-20230828-00140

Abstract

Abstract:

The standard treatment mode for locally advanced operable esophageal carcinoma is neoadjuvant chemoradiotherapy combined with radical esophagectomy. However， considering the clinical need for organ retention， the treatment strategies for those achieving complete clinical response after neoadjuvant chemoradiotherapy include watchful waiting （omitting surgery）， delayed or salvage surgery， and strengthened systemic treatment. These treatment strategies can significantly improve the quality of patients' life while ensuring local control and long-term survival. The feasibility and clinical value of these treatment strategies are deeply explored， hoping to provide new treatment ideas for this group of patients.

Key words: Esophageal neoplasms, Chemoradiotherapy， adjuvant, Wait and see, Salvage surgery, Systemic therapy

Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy[J]. Journal of International Oncology, 2023, 50(12): 745-750.

References 30

[1]	Yang Y, Liu Z, Sun Y, et al. Clinical characteristics and survival of esophageal cancer patients: annual report of the surgical treatment in Shanghai Chest Hospital, 2016[J]. J Thorac Dis, 2022, 14(12): 4966-4982. DOI: 10.21037/jtd-22-1672. pmid: 36647485
[2]	Khaitan PG, Holliday T, Carroll A, et al. Can clinical response predict pathologic response following neoadjuvant chemoradiation for esophageal cancer?[J]. J Gastrointest Surg, 2022, 26(7): 1345-1351. DOI: 10.1007/s11605-022-05315-y. pmid: 35414141
[3]	Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470-2045(18)30201-8. pmid: 29861116
[4]	Eyck BM, van der Wilk BJ, Noordman BJ, et al. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer[J]. Trials, 2021, 22(1): 345. DOI: 10.1186/s13063-021-05274-w. pmid: 34001287
[5]	van der Wilk BJ, Noordman BJ, Neijenhuis LKA, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study[J]. Ann Surg, 2021, 274(6): 1009-1016. DOI: 10.1097/SLA.0000000000003636.
[6]	Zhang X, Eyck BM, Yang Y, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study[J]. BMC Cancer, 2020, 20(1): 194. DOI: 10.1186/s12885-020-6669-y. pmid: 32143580
[7]	van der Zijden CJ, Lagarde SM, Hermus M, et al. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of surgery as needed for oesophageal cancer-2[J]. BMC Cancer, 2023, 23(1): 327. DOI: 10.1186/s12885-023-10747-z. pmid: 37038138
[8]	Bedenne L, Mariette C. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (esostrate)[DB/OL]. [2019-12-20]. https://clinicaltrials.gov/ct2/show/NCT02551458.
[9]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2023[EB/OL].[2023-10-16]. https://meeting.csco.org.cn/pdf/web/viewer.html?file=/Upload/Periodical/20231016021009.pdf.
[10]	Yu J, Kim JH, Kim SB, et al. Role of esophagectomy after chemoradiation therapy in patients with locally advanced squamous cell carcinoma: a comparative analysis stratified by clinical response to chemoradiation therapy[J]. Cancer Res Treat, 2022, 54(4): 1148-1156. DOI: 10.4143/crt.2021.885.
[11]	Park J, Yea JW, Oh SA, et al. Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis[J]. Radiat Oncol, 2021, 16(1): 219. DOI: 10.1186/s13014-021-01947-7. pmid: 34775988
[12]	van der Wilk BJ, Eyck BM, Hofstetter WL, et al. Chemoradiotherapy followed by active surveillance versus standard esophagectomy for esophageal cancer: a systematic review and individual patient data meta-analysis[J]. Ann Surg, 2022, 275(3): 467-476. DOI: 10.1097/SLA.0000000000004930.
[13]	Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD010511. DOI: 10.1002/14651858.CD010511.pub2.
[14]	Wang J, Qin J, Jing S, et al. Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: is esophagectomy always necessary? A systematic review and meta-analysis[J]. Thorac Cancer, 2018, 9(12): 1638-1647. DOI: 10.1111/1759-7714.12874. pmid: 30277016
[15]	Goense L, Ruurda JP, Carter BW, et al. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using ¹⁸F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2018, 45(10): 1742-1751. DOI: 10.1007/s00259-018-4011-6.
[16]	Faiz Z, Kats-Ugurlu G, Mui VEM, et al. Locoregional residual esophageal cancer after neo-adjuvant chemoradiotherapy and surgery regarding anatomic site and radiation target fields: a histopathologic evaluation study[J]. Ann Surg, 2022, 275(6): e759-e765. DOI: 10.1097/SLA.0000000000004242.
[17]	Levinsky NC, Wima K, Morris MC, et al. Outcome of delayed versus timely esophagectomy after chemoradiation for esophageal adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2020, 159(6): 2555-2566. DOI: 10.1016/j.jtcvs.2019.09.169. pmid: 31767364
[18]	Faiz Z, Dijksterhuis WPM, Burgerhof JGM, et al. A meta-analysis on salvage surgery as a potentially curative procedure in patients with isolated local recurrent or persistent esophageal cancer after chemoradiotherapy[J]. Eur J Surg Oncol, 2019, 45(6): 931-940. DOI: 10.1016/j.ejso.2018.11.002. pmid: 30447937
[19]	Park SR, Yoon DH, Kim JH, et al. A randomized phase Ⅲ trial on the role of esophagectomy in complete responders to preoperative chemoradiotherapy for esophageal squamous cell carcinoma (ESOPRESSO)[J]. Anticancer Res, 2019, 39(9): 5123-5133. DOI: 10.21873/anticanres.13707.
[20]	Sugawara K, Yagi K, Okumura Y, et al. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T₄ esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2020, 25(4): 552-560. DOI: 10.1007/s10147-019-01590-z. pmid: 31828451
[21]	Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J]. J Thorac Oncol, 2017, 12(2): 368-374. DOI: 10.1016/j.jtho.2016.10.002.
[22]	郭旭峰, 孙益峰, 杨煜, 等. 食管癌根治性放化疗后挽救性手术: 单一手术组18例临床分析[J]. 中华胸心血管外科杂志, 2018, 34(2): 76-78. DOI: 10.3760/cma.j.issn.1001-4497.2018.02.003.
[23]	Eyck BM, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial[J]. J Clin Oncol, 2021, 39(18): 1995-2004. DOI: 10.1200/JCO.20.03614.
[24]	Liu S, Wen J, Yang H, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase Ⅲ trial NEOCRTEC5010[J]. Eur J Cancer, 2020, 138: 113-121. DOI: 10.1016/j.ejca.2020.08.002.
[25]	Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery[J]. J Thorac Cardiovasc Surg, 2019, 157(3): 1249-1259.e5. DOI: 10.1016/j.jtcvs.2018.09.136. pmid: 30655068
[26]	Kermani AT, Bagheri R, Taheri H, et al. Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy[J]. Kardiochir Torakochirurgia Pol, 2019, 16(4): 186-193. DOI: 10.5114/kitp.2019.91388.
[27]	Wang X, Yu N, Cheng G, et al. Prognostic value of circulating tumour DNA during post-radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma[J]. Clin Transl Med, 2022, 12(11): e1116. DOI: 10.1002/ctm2.1116. pmid: 36437506
[28]	Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
[29]	Park S, Sun JM, Choi YL, et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase Ⅱ study[J]. ESMO Open, 2022, 7(1): 100385. DOI: 10.1016/j.esmoop.2022.100385.
[30]	Schizas D, Mylonas KS, Kapsampelis P, et al. Patients under-going surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data[J]. Interact Cardiovasc Thorac Surg, 2020, 31(3): 299-304. DOI: 10.1093/icvts/ivaa116.